Literature DB >> 8843587

Facilitation of DLA-incompatible marrow grafts by donor-specific serum transferrin?

H J Deeg1, W Pierpaoli, S Arrighi, K Seidel, T Graham, R Huss, C Yu, D Myerson, F Schuening, R Storb.   

Abstract

Studies in mice have shown that donor-specific plasma transferrin (TF) given to the recipient in the peritransplant period facilitates engraftment of marrow from histoincompatible donors. Dogs given 920 cGy of total body irradiation (TBI) and infused with marrow from an unrelated major histocompatibility complex (DLA) different donor generally fail to engraft; only approximately 20% of dogs achieve sustained engraftment. We have now investigated in this model whether the infusion of donor-specific plasma TF would facilitate engraftment. Ten dogs were given TBI, followed at 23 h by an intravenous dose of TF, at 24 h by marrow from the same donor, and another dose of TF at 48 h; six dogs also received postgrafting methotrexate (MTX). Seven dogs (three of four without MTX, four of six with MTX) had sustained engraftment, and three dogs failed to engraft. A single dog given third-party TF failed to engraft. Among five dogs not given TF two achieved sustained engraftment. This pilot study suggests that donor-specific TF facilitates engraftment of DLA-incompatible marrow. Further studies are warranted.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8843587     DOI: 10.1016/s0966-3274(96)80004-9

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  2 in total

Review 1.  Iron overload, hematopoietic cell transplantation, and graft-versus-host disease.

Authors:  H Joachim Deeg; Emily Spaulding; Howard M Shulman
Journal:  Leuk Lymphoma       Date:  2009-10

2.  Transplantation of allogeneic T cells alters iron homeostasis in NOD/SCID mice.

Authors:  Steven Bair; Emily Spaulding; Jaakko Parkkinen; Howard M Shulman; Vladimir Lesnikov; Mary Beauchamp; François Canonne-Hergaux; Kris V Kowdley; H Joachim Deeg
Journal:  Blood       Date:  2008-12-23       Impact factor: 22.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.